Endpoints News | Nachrichten

Zeit	Aktuelle Nachrichten
15:35	Vant commander Ramaswamy heads back to Nasdaq with a $150M pitch - are investors ready to forgive Axovant?
Fr	Taiho kicks off $130M Arcus deal with drug option; J&J allies with Merck KGaA to take diabetes drug to China
Fr	George Golumbeski's first stop out of Celgene: Grail; Roivant taps Genentech vet Myrtle Potter for operations role
Fr	After long delay following patient death, FDA lifts trial hold on Advaxis/AstraZeneca combo
Fr	UPDATED: Senate Dems blast Novartis' ties to Trump attorney, claim pharma giant offered misleading explanations in damning report
Fr	Biogen vet George Scangos jumps on the board at upstart MS case manager Octave, backed by Section 32
Fr	Amgen, UCB are back pitching once-rejected osteoporosis drug romo to the FDA - but big hurdles lie ahead
Do	Investigative report calls for renewed scrutiny on Acadia drug; Imbruvica fails in frontline DLBCL PhIII
Do	On the heels of GW's epilepsy win, Wall Street darling Zogenix shares positive PhIII data on rival drug
Do	Hoping to shake Allergan/Shire's dry eye dominance, Oyster Point posts positive Phase IIb data for rival drug
Do	FDA lays down the law on gene therapy, offering guidances on both diseases and procedures
Do	Ramaswamy's Dermavant bags GSK's PhIII-ready psoriasis drug in $330M deal - eyeing a major league contest
Do	Parker Institute scientists herald a cell therapy breakthrough in the lab, using next-gen CRISPR tech to engineer T cells
Do	Genmab puts down $54M for immunotherapy collaboration - ready to spend millions more
Do	VC money booms in Q2, with mega-deals hitting record levels
Do	Thiel-backed Compass adds $49M to A round, bringing total to $132M
Mi	Senator Wyden prods Trump/Pfizer for details, calling drug pricing stunt "long on theatrics, short on relief"
Mi	Novartis joins the Big Pharma exodus out of antibiotics, dumping research, cutting 140 and out-licensing programs
Mi	Bristol-Myers Squibb's Opdivo/Yervoy combo scores colorectal cancer OK; Former Akebia, Merrimack staffers found guilty
Mi	Pfizer reshuffles, splitting into three business units
Mi	12 top China VCs you need to know who are making a transpacific splash (Part 2)
Mi	Novartis punts a late-stage PI3K drug with a worrying safety profile to one of China's upstart biotechs
Mi	Otsuka jumps into the US biotech M&A game, bagging Visterra in $430M buyout
Mi	Trump claims a big win over Big Pharma, forcing Pfizer to walk back drug price hikes
Mi	Forbion raises $270M to tap the potential of European biotech plays

Zeit

Aktuelle Nachrichten

15:35

Vant commander Ramaswamy heads back to Nasdaq with a $150M pitch - are investors ready to forgive Axovant?

Taiho kicks off $130M Arcus deal with drug option; J&J allies with Merck KGaA to take diabetes drug to China

George Golumbeski's first stop out of Celgene: Grail; Roivant taps Genentech vet Myrtle Potter for operations role

After long delay following patient death, FDA lifts trial hold on Advaxis/AstraZeneca combo

UPDATED: Senate Dems blast Novartis' ties to Trump attorney, claim pharma giant offered misleading explanations in damning report

Biogen vet George Scangos jumps on the board at upstart MS case manager Octave, backed by Section 32

Amgen, UCB are back pitching once-rejected osteoporosis drug romo to the FDA - but big hurdles lie ahead

Investigative report calls for renewed scrutiny on Acadia drug; Imbruvica fails in frontline DLBCL PhIII

On the heels of GW's epilepsy win, Wall Street darling Zogenix shares positive PhIII data on rival drug

Hoping to shake Allergan/Shire's dry eye dominance, Oyster Point posts positive Phase IIb data for rival drug

FDA lays down the law on gene therapy, offering guidances on both diseases and procedures

Ramaswamy's Dermavant bags GSK's PhIII-ready psoriasis drug in $330M deal - eyeing a major league contest

Parker Institute scientists herald a cell therapy breakthrough in the lab, using next-gen CRISPR tech to engineer T cells

Genmab puts down $54M for immunotherapy collaboration - ready to spend millions more

VC money booms in Q2, with mega-deals hitting record levels

Thiel-backed Compass adds $49M to A round, bringing total to $132M

Senator Wyden prods Trump/Pfizer for details, calling drug pricing stunt "long on theatrics, short on relief"

Novartis joins the Big Pharma exodus out of antibiotics, dumping research, cutting 140 and out-licensing programs

Bristol-Myers Squibb's Opdivo/Yervoy combo scores colorectal cancer OK; Former Akebia, Merrimack staffers found guilty

Pfizer reshuffles, splitting into three business units

12 top China VCs you need to know who are making a transpacific splash (Part 2)

Novartis punts a late-stage PI3K drug with a worrying safety profile to one of China's upstart biotechs

Otsuka jumps into the US biotech M&A game, bagging Visterra in $430M buyout

Trump claims a big win over Big Pharma, forcing Pfizer to walk back drug price hikes

Forbion raises $270M to tap the potential of European biotech plays

Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von

Indizes	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage

Aktien	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage

Xetra-Orderbuch

Devisen	Kurs	%

Rohstoffe	Kurs	%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)

Aktuelle News von Endpoints News